Compare PFIS & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PFIS | GYRE |
|---|---|---|
| Founded | 1905 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 589.6M | 606.4M |
| IPO Year | 1998 | 2004 |
| Metric | PFIS | GYRE |
|---|---|---|
| Price | $69.71 | $6.01 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $56.00 | $17.00 |
| AVG Volume (30 Days) | 66.7K | ★ 96.7K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | ★ 4.42% | N/A |
| EPS Growth | ★ 493.94 | N/A |
| EPS | ★ 1.47 | N/A |
| Revenue | N/A | ★ $275,000.00 |
| Revenue This Year | $12.01 | $19.88 |
| Revenue Next Year | $5.85 | N/A |
| P/E Ratio | $46.27 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $43.77 | $5.44 |
| 52 Week High | $70.54 | $9.42 |
| Indicator | PFIS | GYRE |
|---|---|---|
| Relative Strength Index (RSI) | 63.95 | 41.79 |
| Support Level | $56.60 | $5.74 |
| Resistance Level | $70.54 | $8.28 |
| Average True Range (ATR) | 1.60 | 0.29 |
| MACD | -0.09 | -0.08 |
| Stochastic Oscillator | 81.97 | 9.33 |
Peoples Financial Services Corp is a bank holding company operating through its subsidiaries. The bank provides a full range of financial services. Its products and services include checking accounts, business accounts, savings accounts, loan products, money market accounts, mortgages, chip-enabled debit cards, credit card processing, equipment finance, working capital lines of credit, and construction loans, and visa master card and advisory services. Its loan portfolio includes Commercial loans, which consist of commercial, commercial real estate, municipal, and other related tax-free loans; and retail loans, which include residential real estate and other consumer loans. The company mainly operates in the United States in Pennsylvania.
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.